Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Drug price controls in the US: A roundtable discussion with experts
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...